Celgene (CELG) Misses Q4 EPS by 4c

Celgene (NASDAQ: CELG) reported Q4 EPS of $1.18, $0.04 worse than the analyst estimate of $1.22. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.54 billion.

GUIDANCE:

Celgene sees Q1 2016 EPS of $1.27-$1.30, versus the consensus of $1.30.

Celgene sees FY2016 EPS of $5.50-$5.70, versus the consensus of $5.69. Celgene sees FY2016 revenue of $10.5-11 billion, versus the consensus of $11.13 billion.

“Celgene delivered outstanding operating and financial results in 2015. Our extraordinary operating momentum and key regulatory approvals in 2015 increase our prospects for significant growth in 2016 and beyond,” said Bob Hugin, Chairman and Chief Executive Officer of Celgene Corporation. “In 2016, we will continue to leverage our global operations and advance our deep and diverse pipeline to accelerate the next generation of transformational medicines.”

For earnings history and earnings-related data on Celgene (CELG) click here.

You May Also Be Interested In

• Charles Schwab (SCHW) EPS edges past estimates, revenue up sequentially but dips YoY
• Biomerica (BMRA) Issues Update on inFoods IBS Expansion
• Goldman Sachs (GS) Tops Q1 EPS by $2.84